Melissa Amann
Family · Saint Louis, MONPI 1275886012
Payments from drug & device makers
Across 88 payments — averaging $19.10 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AstraZeneca$244
- Lilly USA, LLC$221
- Sumitomo Pharma America, Inc.$108
- Exact Sciences$103
- GSK$102
- Corcept Therapeutics$101
- plus $801 from 22 others
What the payments were for
- Food & beverage$1,681100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AstraZeneca | 13 | $244 |
| Lilly USA, LLC | 11 | $221 |
| Sumitomo Pharma America, Inc. | 5 | $108 |
| Exact Sciences | 5 | $103 |
| GSK | 6 | $102 |
| Corcept Therapeutics | 4 | $101 |
| Novo Nordisk | 6 | $94 |
| Boehringer Ingelheim | 4 | $77 |
| AbbVie | 3 | $74 |
| Amgen | 4 | $68 |
| Averitas Pharma Inc. | 3 | $67 |
| Merck | 4 | $61 |
| Pfizer | 3 | $47 |
| Xeris Pharmaceuticals, Inc. | 2 | $36 |
| Bayer | 2 | $34 |
| Dexcom, Inc. | 1 | $27 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 1 | $22 |
| Gilead | 1 | $21 |
| Otsuka America Pharmaceutical, Inc. | 1 | $20 |
| Optinose US, Inc. | 1 | $19 |
| Mylan Specialty L.p. | 1 | $19 |
| Embecta Corp. | 1 | $18 |
| Astellas Pharma US Inc | 1 | $18 |
| E.r. Squibb & Sons, L.L.C. | 1 | $17 |
| Tactile Systems Technology Inc | 1 | $17 |
| Abbott | 1 | $16 |
| Verona Pharma, Inc. | 1 | $15 |
| Electromed, Inc. | 1 | $14 |
How this compares
$1,681 in reported general payments places this provider in the 75th percentile of 3,812 family providers in Missouri.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 13 | $17,638 |
| FarxigaDapagliflozin Propanediol | 11 | $12,596 |
| AbrysvoRsv Vacc, Pref A And Pref B/Pf | 41 | $11,443 |
| JardianceEmpagliflozin | 11 | $10,365 |
| Repatha SureclickEvolocumab | 16 | $9,495 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 14 | $8,631 |
| Atorvastatin Calcium | 116 | $1,099 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 40 | $1,027 |
| Levothyroxine Sodium | 108 | $973 |
| Mirtazapine | 25 | $964 |
| Fluticasone Propionate | 68 | $910 |
| Omeprazole | 73 | $745 |
| SynthroidLevothyroxine Sodium | 13 | $628 |
| Venlafaxine Hcl ErVenlafaxine Hcl | 19 | $578 |
| Duloxetine Hcl | 31 | $543 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Novo NordiskOzempic | $94 | $17,63813 claims |
| AstraZenecaFarxiga | $244 | $12,59611 claims |
| PfizerAbrysvo | $47 | $11,44341 claims |
| Boehringer IngelheimJardiance | $77 | $10,36511 claims |
| GSKTrelegy Ellipta | $102 | $8,63114 claims |
| AbbVieSynthroid | $74 | $62813 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 3,812 family providers in Missouri.
Other family in Saint Louis
- Rebecca SeabaughSaint Louis$68K
- Jordan PerezSaint Louis$43K
- Lindsay GwaltneySaint Louis$28K
- Sara WoottenSaint Louis$21K
- Kelly RobertsSaint Louis$17K
- Matthew CarySaint Louis$15K
- Philip DudakSaint Louis$14K
- Kenan SahbazSaint Louis$14K
- Nicole CarrSaint Louis$14K
- Ashley GarrettSaint Louis$12K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.